A5091686594- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease and Transplantation
- Genetic and Kidney Cyst Diseases
- Drug Transport and Resistance Mechanisms
- Hepatitis B Virus Studies
- Organ Transplantation Techniques and Outcomes
- Endoplasmic Reticulum Stress and Disease
- RNA modifications and cancer
- Pediatric Hepatobiliary Diseases and Treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Pancreatic function and diabetes
- Cancer-related gene regulation
- Pancreatitis Pathology and Treatment
- Fibroblast Growth Factor Research
- Hepatitis C virus research
- Immune Cell Function and Interaction
- Kruppel-like factors research
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- Wnt/β-catenin signaling in development and cancer
- Neuroendocrine Tumor Research Advances
Inserm
2015-2024
Université de Bordeaux
2013-2024
Bordeaux Population Health
2015-2024
Centre Hospitalier Universitaire de Bordeaux
2007-2024
Sorbonne Université
2022
Centre de Recherche des Cordeliers
2022
Université Paris Cité
2008-2022
Hôpital Saint-André
2004-2018
Hôpital Pellegrin
1998-2018
Translational Research in Oncology
2016
Hepatocellular carcinomas (HCCs) are a heterogeneous group of tumors that differ in risk factors and genetic alterations. We further investigated transcriptome-genotype-phenotype correlations HCC. Global transcriptome analyses were performed on 57 HCCs 3 hepatocellular adenomas validated by quantitative RT-PCR using 63 additional HCCs. determined loss heterozygosity, gene mutations, promoter methylation CDH1 CDKN2A , HBV DNA copy number for each tumor. Unsupervised analysis identified 6...
Hepatocellular adenomas are benign tumors that can be difficult to diagnose. To refine their classification, we performed a comprehensive analysis of genetic, pathological, and clinical features. A multicentric series 96 liver with firm or possible diagnosis hepatocellular adenoma was reviewed by pathologists. In all cases, the genes coding for hepatocyte nuclear factor 1alpha (HNF1alpha) beta-catenin were sequenced. No mutated in both HNF1alpha enabling classified into 3 groups, according...
The work of liver stem cell biologists, largely carried out in rodent models, has now started to manifest human investigations and applications. We can recognize complex regenerative processes tissue specimens that had only been suspected for decades, but we also struggle describe what see tissues a way takes into account the findings from animal investigations, using language derived species not, fact, so much like our own. This international group pathologists hepatologists, most whom are...
Molecular classifications defining new tumor subtypes have been recently refined with genetic and transcriptomic analyses of benign malignant hepatocellular tumors. Here, we performed microRNA (miRNA) profiling in two series fully annotated liver tumors to uncover associations between oncogene/tumor suppressor mutations clinical pathological features. Expression levels 250 miRNAs 46 were compared those 4 normal samples quantitative reverse-transcriptase polymerase chain reaction. associated...
Somatic mutations activating telomerase reverse-trancriptase promoter were recently identified in several tumour types. Here we identify frequent similar human hepatocellular carcinomas (59%), cirrhotic preneoplastic macronodules (25%) and adenomas with malignant transformation (44%). In tumours, reverse-transcripase- CTNNB1-activating are significantly associated. Moreover, preliminary data suggest that can increase the expression of transcript. conclusion, mutation is earliest recurrent...
Hepatocellular adenomas (HCA) with activated β-catenin present a high risk of malignant transformation. To permit robust routine diagnosis to allow for HCA subtype classification, we searched new useful markers. We analyzed the expression candidate genes by quantitative reverse transcription polymerase chain reaction QRT-PCR followed immunohistochemistry validate their specificity and sensitivity according hepatocyte nuclear factor 1 alpha (HNF1α) mutations as well inflammatory phenotype....
We took advantage of the reported genotype/phenotype classification to analyze our surgical series hepatocellular adenoma (HCA). The without specific known etiologies included 128 cases (116 women). number nodules varies from single, <5, and ≥5 in 78, 38, 12 cases, respectively. resection was complete 95 cases. identified 46 HNF1α-inactivated HCAs (44 women), 63 inflammatory (IHCA, 53 women) which nine were also β-catenin–activated, seven β-catenin–activated (all women); six additional had...
Abstract Hepatocellular adenomas (HCAs) are a group of benign tumors forming three molecular pathological subgroups: (1) hepatocyte nuclear factor 1α (HNF-1α)–inactivated, (2) β-catenin–activated, and (3) inflammatory. Some HCAs present both β-catenin activation inflammation. We analyzed magnetic resonance imaging (MRI) data for correlations between features on classification HCAs. included 50 cases which pathology specimens were classified into groups based immunohistochemical staining. Two...
Genetic determinants of the early steps carcinogenesis on cirrhosis are still poorly understood. We aimed to evaluate occurrence telomerase reverse transcriptase (TERT) promoter mutations in transformation cirrhotic nodules into hepatocellular carcinoma (HCC). analyzed a series 268 liver samples, including 96 developed 58 patients with and 114 additional cirrhosis. All samples were screened for TERT mutations, 31 nodules, 10 genes recurrently mutated HCC. Immunohistochemistry (IHC) analyses...
CTNNB1 mutations activating ß-catenin are frequent somatic events in hepatocellular carcinoma (HCC) and adenoma (HCA), particularly associated with a risk of malignant transformation. We aimed to understand the relationship between mutation types, tumor phenotype, level activation To this purpose, spectrum was analyzed 220 HCAs, 373 HCCs, 17 borderline HCA/HCC lesions. assessed tumors by quantitative reverse-transcriptase polymerase chain reaction immunohistochemistry (IHC), cellulo...
Inflammatory hepatocellular adenomas (IHCAs) are benign liver tumors. 60% of these tumors have IL-6 signal transducer (IL6ST; gp130) mutations that activate interleukin 6 (IL-6) signaling. Here, we report 12% IHCA subsets lacking IL6ST harbor somatic and activator transcription 3 (STAT3) (6/49). Most amino acid substitutions in the SH2 domain directs STAT3 dimerization. In contrast to wild-type STAT3, mutants constitutively activated signaling pathway independent ligand cells. Indeed, Y640...
Glutamine synthetase (GS) is a useful marker in tumour liver pathology, including hepatocellular adenomas and nodules cirrhosis. We investigated the use of GS as various clinical situations, which FNH diagnosis had been firmly established to determine its contribution diagnosis.Seventy-nine cases resected FNH, all on normal (or occasionally steatotic) livers, were retrieved from our collection. The control group was composed well-differentiated carcinoma. following stains: H&E, Masson's...
Hepatocellular adenomas (HCA) are rare benign tumours occurring mainly in women under oral contraceptives. HCA bleed frequently and transform rarely into hepatocellular carcinoma. Identification of genes recurrently mutated good genotype/phenotype correlations provided the basis a pathomolecular classification different subgroups, characterized using immunohistochemical markers. HNF1A-mutated HCA: Biallelic-inactivating mutations HNF1A gene identified 35-40% HCA. HNF1alpha-inactivated...